Why is Nimbus, an AI pharmaceutical company, favored by Bill Gates?

On September 13, Nimbus Therapeutics announced a $125 million funding round
.

Founded in 2009 in Cambridge, Massachusetts, Nimbus Therapeutics is a structure-based drug discovery and biotechnology company
that develops and designs breakthrough drugs.

The business model that Jeb Keiper brings to Nimbus's success

Mr.

Prior to joining Nimbus, Mr.

"Jeb has been the key to Nimbus' success over the past four years, and we are confident that he will lead the company into the future and continue to successfully develop the pipeline," said
Bruce Booth, Chairman and Co-founder of Nimbus.

"Nimbus pioneers new ways to discover and develop important drugs for patients using a globally distributed, virtualized operating model," Keiper emphasized
.

Nimbus Therapeutics was founded in the United States in 2009 by Bruce Booth and Ramy Farid to design and develop breakthrough drugs for the treatment of serious diseases, including metabolic diseases, cancer, and immunoinflammatory diseases
.

Using its powerful drug discovery engine, Nimbus Therapeutics has created small molecule compounds that target proteins that are fundamental drivers of highly prevalent pathology in human disease, and Nimbus has solved problems
that other drugmakers have struggled to solve.

Why is it favored by capital? $125 million in private financing

This isn't the first time Nimbus Therapeutics has gained capital favor, and this $125 million round is already its Series F round
.

Figure 1 Bruce Booth (Source: Nimbus Therapeutics)

In 2015, a $43 million Series B round of funding was led by Pfizer Ventures and Lightstone Ventures, while the company officially changed its name to Nimbus Therapeutics by Nimbus Discovery to show that it had transformed into a clinical-stage company
。 Its leading project for inhibitors of nonalcoholic steatohepatitis, Acetyl CoA Carboxylase (ACC), demonstrates the company's ability
to accelerate the discovery, design, optimization and clinical advancement of drug candidates through the deep integration of machine learning, chemistry, and pharmacology 。 The R&D program was subsequently acquired in April 2016 along with Nimbus Apollo, Inc.

Subsequently, in June 2018, October 2020 and July 2021, Nimbus Therapeutics received another $65 million, $60 million and $105 million in investments
, respectively.

Multiple product lines offer endless promises

At present, Nimbus Therapeutics main product line is the oral allosteric tyrosine kinase 2 (tyrosine kinase 2, TYK2) inhibitor NDI-034858 for the treatment of moderate and severe plaque psoriasis and active psoriatic arthritis, hematopoietic progenitor kinase 1 for solid tumor treatment 1, HPK1) inhibitor NDI-101150 has entered the clinical trial stage, which is also the two product pipelines
mainly supported by this round of investment.

Figure 2 Nimbus Therapeutics' current product pipeline (Source: Nimbus Therapeutics official website)

01 NDI-034858

Psoriasis is a systemic immune-mediated disease
.

02 NDI-101150

Nimbus' HPK1 inhibitor NDI-101150 reached a long-term strategic research and development cooperation
with Celgene in 2019.

"Strong investor support is a testament to the prospects of Nimbus' clinical and preclinical R&D pipelines, as well as the success of
our drug discovery engine.

Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology – Nimbus (nimbustx.
com)